Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew N Priest

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
European Radiology|June 9, 2022
Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task forceOliver Lukas Sedlaczek, Jens Kleesiek, Ferdia A Gallagher, et al.
Scientific Reports|July 26, 2019
Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancerSurrin S Deen, Andrew N Priest, Mary A McLean, et al.
BMJ Open|October 26, 2024
Multiarm, non-randomised, single-centre feasibility study-investigation of the differential biology between benign and malignant renal masses using advanced magnetic resonance imaging techniques (IBM-Renal): protocolInes Horvat-Menih, Mary A McLean, Maria Jesus Zamora-Morales, et al.
Kidney International Reports|June 30, 2026
Prospective Study of Multiparametric Renal MRI for CKD Progression (AFiRM)Susan Francis, Charlotte E Buchanan, Victoria Chester, et al.
Nature Communications|January 25, 2022
Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancerNikita Sushentsev, Mary A McLean, Anne Y Warren, et al.
Nature Communications|March 8, 2022
Author Correction: Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancerNikita Sushentsev, Mary A McLean, Anne Y Warren, et al.
Communications Medicine|January 13, 2026
Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarised <sup>13</sup>C-MRI and mass spectrometry imagingInes Horvat-Menih, Ruth Casey, James Denholm, et al.
British Journal of Cancer|June 23, 2022
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)Grant D Stewart, Sarah J Welsh, Stephan Ursprung, et al.
Abdominal Radiology (New York)|December 10, 2025
Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-<sup>13</sup> C]pyruvate MRIInes Horvat-Menih, Mary A McLean, Jonathan Birchall, et al.
Cancers|January 21, 2022
Hyperpolarized <sup>13</sup>C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma-A Proof of Principle StudyStephan Ursprung, Ramona Woitek, Mary A McLean, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
European Radiology|June 9, 2022
Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task forceOliver Lukas Sedlaczek, Jens Kleesiek, Ferdia A Gallagher, et al.
Scientific Reports|July 26, 2019
Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancerSurrin S Deen, Andrew N Priest, Mary A McLean, et al.
BMJ Open|October 26, 2024
Multiarm, non-randomised, single-centre feasibility study-investigation of the differential biology between benign and malignant renal masses using advanced magnetic resonance imaging techniques (IBM-Renal): protocolInes Horvat-Menih, Mary A McLean, Maria Jesus Zamora-Morales, et al.
Kidney International Reports|June 30, 2026
Prospective Study of Multiparametric Renal MRI for CKD Progression (AFiRM)Susan Francis, Charlotte E Buchanan, Victoria Chester, et al.
Nature Communications|January 25, 2022
Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancerNikita Sushentsev, Mary A McLean, Anne Y Warren, et al.
Nature Communications|March 8, 2022
Author Correction: Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancerNikita Sushentsev, Mary A McLean, Anne Y Warren, et al.
Communications Medicine|January 13, 2026
Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarised <sup>13</sup>C-MRI and mass spectrometry imagingInes Horvat-Menih, Ruth Casey, James Denholm, et al.
British Journal of Cancer|June 23, 2022
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)Grant D Stewart, Sarah J Welsh, Stephan Ursprung, et al.
Abdominal Radiology (New York)|December 10, 2025
Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-<sup>13</sup> C]pyruvate MRIInes Horvat-Menih, Mary A McLean, Jonathan Birchall, et al.
Cancers|January 21, 2022
Hyperpolarized <sup>13</sup>C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma-A Proof of Principle StudyStephan Ursprung, Ramona Woitek, Mary A McLean, et al.
Pageof 9